For years, the Fructose Model has made a simple but consequential argument: fructose is not merely another source of calories. It can act as a metabolic signal—one that tells the body to conserve energy, seek more food and store fuel for later.

At the center of that signal is one enzyme: ketohexokinase, also called KHK or fructokinase.

In 2026, two major scientific reviews brought the entire case into focus. One, published in Nature Metabolism, describes fructose as both a calorie and a regulator of metabolic health and disease. The other, published in Pharmacological Research, identifies KHK as a central mediator of fructose-related pathology and a promising therapeutic target.

Placed side by side, the papers read like the two halves of the Fructose Model. One explains why fructose can function as a biological signal. The other identifies the control point through which that signal becomes action.

One paper defines fructose as the signal. The other identifies KHK as the target.

Pharmaceutical companies are already testing drugs against that control point in people.

And among the compounds named in the KHK-inhibitor literature is luteolin—the primary ingredient around which LIV3 built SugarShield.

This is no longer a loose collection of interesting clues. The science is converging.

Fructose is a signal, not just a sugar

Glucose and fructose contain the same number of calories per gram. They do not send the same metabolic message.

Glucose is a broadly available fuel. Its metabolism is surrounded by regulatory brakes that respond to the cell's energy state. Fructose follows a different route. It is rapidly converted by KHK into fructose-1-phosphate, committing it to a pathway that can consume ATP quickly and temporarily sequester phosphate.

That first step can begin a recognizable cascade:

Fructose → KHK → fructose-1-phosphate → ATP consumption → AMP breakdown → uric acid

The pathway also supplies carbon for fat synthesis and interacts with metabolic signaling involved in energy storage. In evolutionary terms, that makes sense. When food was seasonal or scarce, a signal that promoted foraging, conservation and fat storage could improve survival.

The problem is not that the system is defective. The problem is that an elegant survival system is now operating in an environment of constant access to concentrated sugar, refined carbohydrates and food.

The 2026 Nature Metabolism review pulls these pieces together. It distinguishes fructose from glucose, describes fructose's role as a signal of metabolic plenty, explains the ATP and uric-acid pathway, and gives serious attention to fructose produced inside the body from glucose through the polyol pathway. Its conclusion is not that fructose is simply “empty calories.” It is that fructose can help regulate whether energy is burned, sought or stored. Johnson and colleagues, 2026.

That is the first half of the case.

KHK is the control point

If fructose is the signal, KHK is the gateway.

KHK performs the first committed step in the body's main fructose pathway. Block KHK and fructose cannot proceed normally through that route. Remove KHK in experimental models and many of fructose's downstream metabolic effects are reduced. In people born without functional KHK, the resulting condition—essential fructosuria—is generally benign.

That combination makes KHK unusually attractive: it is upstream, specific, measurable and apparently nonessential to normal life.

The 2026 Pharmacological Research review calls KHK a core mediator of fructose-driven pathogenesis and surveys its role across fatty liver disease, obesity, kidney disease, metabolic reprogramming and other areas. It also reviews the growing development of pharmaceutical KHK inhibitors and identifies KHK as an actionable therapeutic target. Zhang and colleagues, 2026.

That is the second half of the case.

The implications are hard to miss. If a major review now describes fructose as a regulator of metabolic health, and another identifies the enzyme that begins fructose metabolism as a central therapeutic target, then the central architecture of the Fructose Model is no longer sitting at the edge of metabolic research.

It is becoming part of the research agenda.

Pharma has already validated that KHK can be changed in people

The strongest validation does not come from theory. It comes from drug development.

Pfizer tested the oral KHK inhibitor PF-06835919 in a 16-week randomized trial involving 164 adults with fatty liver disease and type 2 diabetes. At the higher tested dose, the drug significantly reduced MRI-measured liver fat relative to placebo. HbA1c did not improve significantly, which tells us that one intervention did not solve every feature of metabolic dysfunction. But the central result remains: changing KHK changed a measurable metabolic outcome in people. Saxena and colleagues, 2023.

Eli Lilly has since tested another oral KHK inhibitor, LY3522348, in 65 healthy adults. After participants consumed a fructose beverage, plasma fructose rose in a dose-dependent pattern—exactly the direction expected when less fructose is being processed through KHK. The study demonstrated human target engagement. Fukuda and colleagues, 2025.

These programs answer three important questions:

1. Can KHK be inhibited in humans? Yes.
2. Can that inhibition be measured? Yes.
3. Can changing the pathway alter a meaningful metabolic marker? Yes.

This does not prove that every KHK inhibitor will produce the same result, or that KHK alone explains every metabolic condition. It establishes something more foundational: the target is real, accessible and biologically consequential in people.

Luteolin is already on the KHK map

Luteolin did not arrive in this story because it is a fashionable antioxidant. It arrived because researchers measured it against the enzyme.

In a 2017 Nature Communications study, luteolin inhibited fructokinase in a biochemical assay, with a reported IC50 of 11.2 micromolar, and inhibited fructokinase activity in a human proximal-tubule cell system. In mice, intravenous luteolin also changed fructose handling in the expected direction and reduced injury in a model where KHK had independently been shown to contribute to the damage. Andres-Hernando and colleagues, 2017.

The 2026 KHK review now places luteolin within the broader landscape of compounds being investigated as KHK inhibitors. Our luteolin and KHK evidence review examines the underlying experiment in greater depth.

That matters. The pharmaceutical industry did not create the target and LIV3 did not invent it. Independent research has converged on the same enzyme from different directions: evolutionary metabolism, cellular energetics, disease models, human drug trials and natural-compound screening.

KHK is where those lines meet.

Human luteolin research adds another piece

Luteolin has not yet been tested in a human KHK target-engagement trial. But it is not confined entirely to cell and animal research.

In a six-month randomized, double-blind trial, 100 adults with metabolic syndrome received either placebo or Altilix, a multi-component supplement containing chlorogenic acids and luteolin-related compounds. Compared with placebo, the Altilix group improved across several relevant measures, including waist circumference, HbA1c, an estimate of insulin resistance and a calculated fatty-liver score. Castellino and colleagues, 2019.

That trial did not isolate luteolin, did not test SugarShield and did not measure KHK activity. It therefore cannot tell us which ingredient produced which effect or whether KHK inhibition caused the outcome.

But it does add a human signal in the expected territory: an oral formulation containing luteolin was associated with movement in metabolic markers that matter to the broader model.

The evidence now forms a coherent sequence:

• fructose acts as a metabolic signal;
• KHK initiates its distinctive pathway;
• inhibiting KHK produces measurable target engagement in humans;
• pharmaceutical KHK inhibition has changed liver fat in a randomized trial;
• luteolin directly inhibits KHK in preclinical experiments;
• and a different luteolin-containing formulation has moved relevant metabolic markers in people.

Those are not interchangeable findings. They are consecutive pieces of the same research program.

What is actually left to prove?

The remaining question is narrower than it once was.

At the level of mechanism, we are no longer asking whether fructose can function as a metabolic signal. We are no longer asking whether KHK sits at the entrance to its distinctive pathway. We are no longer asking whether KHK can be inhibited in humans or whether changing it can affect human biology.

The central target has been substantially validated.

The next question is whether oral luteolin, at a particular dose and in a particular formulation, can engage KHK strongly enough in people to produce a measurable effect. That is a target-engagement and delivery question—not a reason to discard the model that led us there.

A direct study is straightforward to imagine: randomize people to luteolin or placebo, standardize diet, administer a controlled fructose challenge, and measure plasma and urinary fructose alongside uric acid, glucose, insulin and luteolin metabolites.

The result would tell us whether oral luteolin changes human fructose handling in a pattern consistent with KHK inhibition.

Why LIV3 built SugarShield

This is the research logic behind SugarShield.

SugarShield is not a drug, and the finished product has not been used in the KHK or Altilix studies described above. It is a practical expression of a precise hypothesis: if luteolin can inhibit KHK in experimental systems, can a thoughtfully delivered oral formulation meaningfully influence the way people experience fructose-related cravings and energy regulation?

What keeps that question compelling for us is not only the literature. It is what customers repeatedly describe when they use SugarShield.

The customer pattern is difficult to ignore

The striking feature of the customer response is not one isolated benefit. It is the consistency of the pattern.

Across reviews, messages and conversations, customers often describe several changes appearing together:

• cravings and “food noise” become quieter;
• energy feels steadier, without the same swings and crashes;
• weight becomes easier to manage, or begins moving after feeling stubborn;
• puffiness, soreness or the subjective feeling of being inflamed eases;
• thinking feels clearer and brain fog becomes less intrusive.

These are customer observations, not controlled clinical endpoints, and they do not prove that SugarShield is inhibiting KHK in people. But the pattern matters. If the fructose pathway helps coordinate appetite, cellular energy conservation, fat storage, uric-acid production and mitochondrial stress, a meaningful change should be experienced as a cluster—not as one isolated number on a lab report.

Customers are not all using the same scientific language, yet they repeatedly describe changes in the same connected domains predicted by the model. That pattern cannot replace a human target-engagement study. It tells us why that study is worth doing.

SugarShield was not assembled as a random collection of wellness ingredients and given a story afterward. It was built around a named enzyme, a coherent biological pathway and a testable prediction—and the customer pattern is strikingly consistent with that prediction.

The case for KHK as a central, druggable control point is approaching closed. The case for how strongly a particular luteolin formulation can influence that target in people is the next chapter.

Remember the name: ketohexokinase. Fructose sends the signal. KHK opens the pathway. Pharma is targeting it. Luteolin is already named.

Written by Chris Mearns, founder of LIV3 Health. LIV3 develops and sells SugarShield, a dietary supplement containing luteolin. SugarShield was not used in the studies cited above. The Altilix research tested a different, multi-component formulation.

Sources

1. Johnson et al., Nature Metabolism (2026) — fructose as a metabolic signal, endogenous fructose and the survival model.
2. Zhang et al., Pharmacological Research (2026) — KHK biology, disease relevance and inhibitor development.
3. Saxena et al., Diabetes, Obesity and Metabolism (2023) — randomized human trial of PF-06835919.
4. Fukuda et al., Diabetes Therapy (2025) — first-in-human study of LY3522348.
5. Andres-Hernando et al., Nature Communications (2017) — biochemical, human-cell and mouse luteolin/KHK experiments.
6. Castellino et al., Nutrients (2019) — randomized Altilix trial in adults with metabolic syndrome.